Form 4: Enliven Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Helen Louise Collins, CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc., sold 5,000 shares of common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 5,000 Common Stock at $2.48 ($12,400) on September 17, 2026; holds 30,000 after (Direct).
- Open-market sale: disposed of 2,916 Common Stock at $50.03 ($145,891) on September 17, 2026; holds 27,084 after (Direct).
- Open-market sale: disposed of 1,844 Common Stock at $50.71 ($93,507) on September 17, 2026; holds 25,240 after (Direct).
- Open-market sale: disposed of 240 Common Stock at $51.48 ($12,356) on September 17, 2026; holds 25,000 after (Direct).
- Option exercise/conversion: disposed of 5,000 Stock Option (right to buy) on September 17, 2026; holds 106,268 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $251,754 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Helen Louise Collins — Officer (CHIEF MEDICAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Common Stock | 5,000 | $2 | $12.4K | 30,000 |
| 2026-09-17 | Open-market sale | Common Stock | 2,916 | $50 | $145.9K | 27,084 |
| 2026-09-17 | Open-market sale | Common Stock | 1,844 | $51 | $93.5K | 25,240 |
| 2026-09-17 | Open-market sale | Common Stock | 240 | $51 | $12.4K | 25,000 |
| 2026-09-17 | Option exercise/conversion | Stock Option (right to buy) | 5,000 | — | — | 106,268 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (5,000 shares) |
| 2026-09-17 | Open-market sale (2,916 shares) |
| 2026-09-17 | Open-market sale (1,844 shares) |
| 2026-09-17 | Open-market sale (240 shares) |
| 2026-09-17 | Option exercise/conversion (5,000 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., bearish, Helen Louise Collins
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.